Detalhe da pesquisa
1.
Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.
Biol Blood Marrow Transplant
; 20(8): 1139-44, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24727332
2.
Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.
J Immunol
; 189(11): 5476-84, 2012 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23105141
3.
Canagliflozin review - safety and efficacy profile in patients with T2DM.
Diabetes Metab Syndr Obes
; 12: 209-215, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30787627
4.
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.
Clin Cancer Res
; 24(14): 3386-3396, 2018 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29661776
5.
Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target.
Front Immunol
; 8: 1975, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29422892
6.
Cancer immunotherapies, their safety and toxicity.
Expert Opin Drug Saf
; 12(5): 631-45, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23668362
7.
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.
Clin Cancer Res
; 19(1): 247-57, 2013 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23147993
8.
Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.
Leukemia
; 31(1): 234-237, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27573556